Security National Bank of Sioux City Iowa IA Boosts Stock Position in Johnson & Johnson $JNJ

Security National Bank of Sioux City Iowa IA boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 27.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,143 shares of the company’s stock after acquiring an additional 3,878 shares during the quarter. Johnson & Johnson accounts for approximately 1.9% of Security National Bank of Sioux City Iowa IA’s investment portfolio, making the stock its 12th biggest position. Security National Bank of Sioux City Iowa IA’s holdings in Johnson & Johnson were worth $4,608,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Reynders McVeigh Capital Management LLC boosted its holdings in Johnson & Johnson by 0.7% in the second quarter. Reynders McVeigh Capital Management LLC now owns 76,513 shares of the company’s stock valued at $19,432,000 after purchasing an additional 499 shares during the period. Bullseye Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $63,000. Talon Private Wealth LLC lifted its position in shares of Johnson & Johnson by 89.5% during the 2nd quarter. Talon Private Wealth LLC now owns 10,588 shares of the company’s stock worth $2,689,000 after purchasing an additional 5,002 shares during the last quarter. U S Wealth Group LLC. lifted its position in shares of Johnson & Johnson by 15.1% during the 2nd quarter. U S Wealth Group LLC. now owns 17,259 shares of the company’s stock worth $4,383,000 after purchasing an additional 2,266 shares during the last quarter. Finally, Miramontes Capital LLC grew its stake in shares of Johnson & Johnson by 20.5% during the second quarter. Miramontes Capital LLC now owns 7,584 shares of the company’s stock worth $1,926,000 after purchasing an additional 1,289 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson remains attractive to income-focused investors as a Dividend Aristocrat with 64 consecutive years of dividend increases. Analysts also point to its defensive characteristics, healthy balance sheet, buyback potential and ability to provide steady cash returns amid economic and inflation uncertainty. 3 Strong Buy Dividend Aristocrat Stocks to Generate Steady Cash
• Positive Sentiment: Recent drug launches, pipeline progress and oncology data are supporting the growth case. Management has highlighted underlying growth despite the loss of Stelara sales, with revenue reportedly rising 5.6% after excluding a significant Stelara-related drag. J&J Up 18% in Three Months
• Neutral Sentiment: Reports that J&J may sell its DePuy Synthes orthopedic unit for approximately $20 billion have renewed focus on portfolio strategy and capital allocation. A transaction could unlock value or fund growth, but the sale remains only potential and could reduce the company’s MedTech scale. J&J Faces a Fresh Valuation Test on DePuy Sale Talk
• Neutral Sentiment: CEO Joaquin Duato’s appointment to PepsiCo’s independent board, effective December 1, adds visibility to J&J’s leadership but is not a direct change to J&J’s earnings outlook. PepsiCo Welcomes Joaquin Duato to Its Board
• Negative Sentiment: Investors remain concerned about Stelara’s patent loss, MedTech weakness and billions of dollars in talc-related litigation liabilities. In addition, J&J’s elevated valuation after its strong run may limit upside unless operating results continue to exceed expectations. Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Analyst Ratings Changes

A number of research firms have weighed in on JNJ. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research note on Monday, August 3rd. Bank of America increased their price objective on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a report on Friday, July 10th. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. Argus set a $300.00 price target on Johnson & Johnson in a report on Wednesday, July 29th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $274.13.

Johnson & Johnson Stock Performance

Shares of JNJ traded down $0.25 during mid-day trading on Friday, hitting $269.97. 16,409,193 shares of the company’s stock were exchanged, compared to its average volume of 8,077,023. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The business’s 50 day moving average is $263.49 and its two-hundred day moving average is $246.55. The firm has a market capitalization of $650.61 billion, a P/E ratio of 31.28, a P/E/G ratio of 2.55 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter in the previous year, the firm posted $2.77 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.